FLT3-ITD mutations are clearly linked with proliferative AML (e.g., higher WBC, leukocytosis, and blast %) and also a higher risk of relapse, implicating declined overall survival and a poor prognosis [19]. This evidence concerns the gene FLT3 and acute myeloid leukemia.